Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
European Journal of Neurology2020Vol. 28(5), pp. 1609–1616
Citations Over TimeTop 10% of 2020 papers
Gabriel Bsteh, Harald Hegen, Katharina A. Riedl, Patrick Altmann, Michael Auer, Klaus Berek, Franziska Di Pauli, Rainer Ehling, Barbara Kornek, Tobias Monschein, Walter Rinner, Christiane Schmied, Sebastian Wurth, Karin Zebenholzer, Anne Zinganell, Tobias Zrzavy, Gudrun Zulehner, Florian Deisenhammer, Paulus Rommer, Fritz Leutmezer, Thomas Berger
Abstract
The composite VIAADISC score is a valuable tool to inform and support patients and neurologists in the process of decision making to discontinue injectable DMTs.
Related Papers
- → Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis(2003)144 cited
- → Glatiramer in the treatment of multiple sclerosis-0(2011)13 cited
- [Multiple sclerosis: current therapies and future perspectives].(2011)
- Treatment for delaying conversion of the first demyelinating event to Multiple Sclerosis: a cochrane review on use of recombinant interferon beta or glatiramer acetate(2005)
- → Clinical course of multiple sclerosis in Japanese patients treated with glatiramer acetate(2017)